SCRIBE THERAPEUTICS INC. (SCTX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $2.77M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $39.17M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $2.77M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $2.77M |
| Deferred revenue · latest quarter (USD) | $39.17M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $27.48M + $11.70M ≈ $39.17M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | $7.92M | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $7.92M − $0.00 ≈ $7.92M |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 102.42M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 2.77M USD | Accounts Payable, Current |
| Total deferred revenue | 39.17M USD | Contract with Customer, Liability · Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | 27.48M USD | Deferred Revenue, Current |
| Deferred revenue due after one year | 11.70M USD | Deferred Revenue, Noncurrent · Contract with Customer, Liability · Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | 7.92M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- $7.92M
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Income taxes payable | $87.00K |
| Operating lease obligations | $5.47M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.77M | $39.17M | (m) | $7.92M | $102.42M | (m) | $27.48M | $11.70M | $7.92M | $0.00 |
| 2025-12-31 | (m) | $4.57M | $41.02M | (m) | $7.49M | $101.28M | (m) | $21.09M | $19.94M | $7.49M | $0.00 |
| 2025-06-30 | (m) | (m) | $60.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $72.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |